# Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

> **NCT06549257** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 56 (actual)

## Conditions studied

- Plasmodium Falciparum Malaria

## Interventions

- **BIOLOGICAL:** Pfs25-IMX313, Pfs48/45

## Key facts

- **NCT ID:** NCT06549257
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549257, "Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06549257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*